Solvonis Therapeutics PLC CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the completion of the company’s acquisition of Awakn Life Sciences and the progress of its lead clinical program.
Tennyson explained that the acquisition positions Solvonis as a biotechnology firm focused on treating addiction and mental health disorders. A key asset from the deal, formerly AWKN-001 and now renamed SVN-001, targets severe alcohol use disorder and is currently in a Phase 3 clinical trial.
"The results of the phase two for that program were groundbreaking," Tennyson said, highlighting that participants improved from 2% sobriety to 86% six months post-treatment. The Phase 3 trial is being conducted in partnership with the UK Department of Health at an unusually low cost of £800,000 – a figure Tennyson noted is “unheard of really, in the biopharmaceutical industry.”
The trial is being carried out within the NHS and supported by UK addiction specialists and the Department of Health and Social Care, adding national relevance to the program.
Tennyson also discussed a second program, SVN-002, focused on alcohol use disorder in the U.S., and outlined plans to integrate Awakn’s assets and grow Solvonis’s team.
Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel and enable notifications for future content.
#SolvonisTherapeutics #AlcoholAddictionTreatment #SVN001 #BiotechNews #Phase3Trial #MentalHealthInnovation #AwaknAcquisition #ClinicalResearch #AddictionRecovery #ProactiveInvestors
